Claims
- 1. A particle comprising:
- a center core of greater than about 90 weight percent microcrystalline cellulose having an average particle size of about 160 to about 220 microns with a particle size standard deviation of from about 75 to about 200 microns;
- pharmaceutically active material coating the center core of microcrystalline cellulose and a tapped bulk density of from about 0.40 to about 0.45 grams per cubic centimeters;
- wherein the coated particle is from about 40 to about 75 weight percent microcrystalline cellulose; pharmaceutically active ingredient is from about 25 to about 60 weight percent; and a particle size of from about 200 to about 325 microns and a particle size standard deviation of from about 30 to about 175 microns.
- 2. The particle of the claim 1 wherein the center core is greater than about 95 weight percent microcrystalline cellulose.
- 3. The particle of claim 1 which additionally contains a polymer coating over the pharmaceutical active ingredient.
- 4. The particle of claim 3 wherein the polymer coating is selected from the group consisting of methylaminoethyl-methacrylate, methacrylic acid esters, cellulose acetate and polyvinylpyrrolidone.
- 5. A method for making a pharmaceutically active particle comprising:
- providing a center core of greater than about 90 weight percent microcrystalline cellulose having an average particle size of about 160 to about 220 microns with a particle size standard deviation of from about 75 to about 200 and a tapped bulk density of from about 0.40 to about 0.45 grams per cubic centimeters;
- coating said microcrystalline cellulose with a pharmaceutically active ingredient;
- wherein the coated particle is from about 40 to about 75 weight percent microcrystalline cellulose; the pharmaceutically active ingredient is from about 25 to about 60 weight percent; has a particle size of from about 200 to about 325 microns; a particle size standard deviation of from about 30 to about 175 microns; wherein the coating of the microcrystalline cellulose is performed in the absence of a granulation step.
- 6. The method of claim 5 wherein the pharmaceutically active materials are deposited on the core via a solution layering process.
- 7. The method of claim 5 where a polymeric coating is applied over the pharmaceutically active material.
- 8. The method of claim 7 wherein the polymeric coating is selected from the group consisting of methylaminoethyl-methacrylate, methacrylic acid esters and or cellulose acetate and polyvinylpyrrolidone.
- 9. The method of claim 8 wherein the coated particles and excipients are compressed to form tablets.
RELATED APPLICATIONS
This application is a divisional application of U.S. Ser. No. 09/148,251, filed on Sep. 4, 1998 is now U.S. Pat. No. 5,997,905, the contents of which are hereby incorporated by reference as if set forth in its entirety.
US Referenced Citations (13)
Foreign Referenced Citations (2)
Number |
Date |
Country |
289733 |
Nov 1996 |
TWX |
9409762 |
Nov 1994 |
WOX |
Non-Patent Literature Citations (3)
Entry |
Avicel PH Microcrystalline Cellulose, NJ, Ph.Eur., JP, BP, FMC Corp., Aug. 3, 1998. |
Avicel PH Microcrystalline Cellulose, NJ, Ph.Eur., JP, BP,; Focut on Differentiated Prod. FMC Corp., 1994. |
Celphere Microcrystalline Cellulose Spheres, FMC orp., Oct. 1995. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
148251 |
Sep 1998 |
|